All In Biotech

Drug Trial Radar · NCT03897205

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients

Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Apr 30, 2019

Primary completion

May 28, 2022

Study completion Nov 16, 2022

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Apr 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an active or chronic active antibody mediated rejection (AMR) after being kidney transplanted. The purpose was also to investigate and compare safety for these two treatments.

Conditions

  • Kidney Transplant Rejection

Interventions

  • ImlifidaseDrug

    Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.

  • Plasma ExchangeOther

    The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of TreatmentTime frame: Start of treatment until 5 days following start of treatment

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Brigham and Women Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • New York University Grossman School of Medicine

    New York, New York

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Prince Alfred Hospital

    Sydney, Australia

  • The Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW

    Vienna, Austria

  • Hôpital Pellegrin

    Bordeaux, France

  • CHU Grenoble Alpes - Néphrologie, dialyse et transplantation

    Grenoble, France

  • Hôpital Saint-Louis. Service de Néphrologie et Transplantation

    Paris, France

  • Hôpital Necker - Service de Néphrologie - Transplantation

    Paris, France

  • Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care

    Berlin, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.